Investment Thesis
ABVC faces an acute liquidity crisis with cash reserves of only $140K against annual operating cash burn of $894K, a current ratio of 0.12x indicating inability to cover near-term obligations, and a 41.9% revenue collapse that has rendered the company deeply unprofitable. The combination of negative operating cash flow, severe net losses, and minimal revenue generation creates existential solvency risk within months.
Strengths
- Minimal leverage with debt-to-equity ratio of 0.01x provides low bankruptcy protection but preserves capital structure
- Positive gross profit of $796K suggests some revenue contribution, though offset by operating expenses
- Stockholders equity of $10.8M provides technical asset cushion against liabilities
Risks
- Critical liquidity crisis: 0.12x current ratio with only $140.3K cash cannot sustain operations burning $894.2K annually, indicating runway of ~6 weeks
- Revenue collapse of 41.9% YoY signals fundamental business failure; $296K quarterly revenue insufficient to cover operating costs of $1.6M+
- Negative free cash flow of $915.4K with no visible path to profitability; unsustainable cash burn in unprofitable biotech/pharma sector
- Zero insider activity in 90 days suggests lack of confidence from management; no capital raises or strategic actions evident
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway (critical threshold: <$100K cash)
- Revenue trend stabilization or further decline YoY
- Operating cash flow recovery to positive territory
- Debt covenant compliance and refinancing/capital raise announcements
Financial Metrics
Revenue
296.0K
Net Income
-1.6M
EPS (Diluted)
$-0.06
Free Cash Flow
-915.4K
Total Assets
19.7M
Cash
140.3K
Profitability Ratios
Gross Margin
268.9%
Operating Margin
-531.2%
Net Margin
-527.1%
ROE
-14.5%
ROA
-7.9%
FCF Margin
-309.3%
Balance Sheet & Liquidity
Current Ratio
0.12x
Quick Ratio
0.12x
Debt/Equity
0.01x
Debt/Assets
35.0%
Interest Coverage
-285.07x
Long-term Debt
124.4K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-19T06:19:33.314761 |
Data as of: 2026-03-31 |
Powered by Claude AI